Politics
FDA's Mifepristone Data Scrutiny
The FDA is under scrutiny for its data on mifepristone, with concerns raised about the robustness of real-world data sources needed for publication.
Coverage timeline — 1 article
The Hill
For the review to withstand the necessary scrutiny it will face upon publication, the FDA must prioritize robust, real-world data sources.
2026-06-18 13:00 UTC